No Data
JW THERAP-B (02126.HK) granted a total of 0.3877 million stock options.
Gelonghui reported on January 6 that JW THERAP-B (02126.HK) announced that on January 6, 2025, (i) a total of 387,740 stock options will be granted at an exercise price of HKD 1.36 per share, according to the terms of the incentive plan adopted after the company's initial public offering on October 14, 2020; and (ii) a total of 77,548 restricted stock units will be granted to two grantees according to the restricted stock unit plan adopted after the company's initial public offering on October 14, 2020.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Express News | JW (Cayman) Therapeutics - Pwc Has Tendered Resignation to Board as Auditor
JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Stock Rockets 31% But Many Are Still Ignoring The Company
No Data
